(NASDAQ: LGVN) Longeveron's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 24.3%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 67.39%.
Longeveron's earnings in 2026 is -$22,429,000.On average, 4 Wall Street analysts forecast LGVN's earnings for 2026 to be -$17,314,249, with the lowest LGVN earnings forecast at -$21,061,153, and the highest LGVN earnings forecast at -$13,081,462. On average, 4 Wall Street analysts forecast LGVN's earnings for 2027 to be -$16,678,863, with the lowest LGVN earnings forecast at -$21,671,621, and the highest LGVN earnings forecast at -$11,119,242.
In 2028, LGVN is forecast to generate -$21,603,099 in earnings, with the lowest earnings forecast at -$20,755,919 and the highest earnings forecast at -$22,238,485.